<DOC>
	<DOCNO>NCT00424983</DOCNO>
	<brief_summary>The primary objective study investigate repeat-dose pharmacokinetic ( PK ) profile zoledronic acid administer every 4 week versus every 12 week , patient treat 9-20 infusion zoledronic acid previous 10-15 month .</brief_summary>
	<brief_title>Study Zoledronic Acid Administered Monthly Versus Every 3 Months Multiple Myeloma Breast Cancer Patients Who Were Treated With Zoledronic Acid Prior Year</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Male female 1875 year age Multiple myeloma breast cancer bone involvement Treatment zoledronic acid bone lesion 1015 month prior entry study total 920 infusion receive . Current active dental problem recent ( within 8 week ) plan dental jaw surgery Active uncontrolled infection , liver , renal disease History treatment intravenous bisphosphonates Diagnosis metabolic bone disorder osteoporosis ( e.g . Paget 's disease ) Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Multiple myeloma</keyword>
	<keyword>breast cancer</keyword>
	<keyword>zoledronic acid</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>